RxDoctor Payments Data

Nyo Lwin, MD

Internal Medicine · Brooklyn, NYNPI 1780843938

Payments from drug & device makers

$788in general payments, 2019–2025

Across 35 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$183
  • AbbVie$144
  • Novo Nordisk$82
  • Exact Sciences$70
  • Bayer$62
  • Lilly USA, LLC$59
  • plus $189 from 5 others

What the payments were for

  • Food & beverage$788100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$788 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$83,591
Medicare patients
263
Services billed
863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$47,168
EliquisApixaban31$40,148
JanuviaSitagliptin Phosphate30$32,394
MounjaroTirzepatide14$21,858
XareltoRivaroxaban25$17,218
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,477
JanumetSitagliptin Phos/Metformin Hcl12$11,049
Breo ElliptaFluticasone/Vilanterol17$6,643
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$6,069
Atorvastatin Calcium461$4,832
Albuterol Sulfate HfaAlbuterol Sulfate137$4,266
VesicareSolifenacin Succinate11$3,968
Novolog FlexpenInsulin Aspart25$3,579
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,793
SymbicortBudesonide/Formoterol Fumarate12$2,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$40,14831 claims
Lilly USA, LLCMounjaro$59$21,85814 claims
GSKTrelegy Ellipta, Breo Ellipta$183$18,11936 claims
AbbVieSynthroid$144$1,18936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →